⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2489118 | 0.75 | — | — | |
| SCHEMBL7443022 | 0.75 | — | — | |
| SCHEMBL1687039 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL11390402 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL29001924 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL29001926 | 0.73 | — | — | |
| SCHEMBL6308518 | 0.70 | CREBBP (0.44) | — | |
| SCHEMBL12345838 | 0.70 | CREBBP (0.44) | — | |
| SCHEMBL48367 | 0.70 | — | — | |
| SCHEMBL16349234 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533354-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20230044941-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2023-02-09 | — | — | US | disclosed |
| CN-114340633-A | Triaryl compounds for the treatment of PD-L1 disease | 凯莫森特里克斯股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3968996-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | ChemoCentryx, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200383979-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2020-12-10 | — | — | US | disclosed |
| WO-2020232256-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-7101883-B2 | Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20030229081-A1 | Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-11 | — | — | US | disclosed |
| WO-2003079986-A2 | URACIL DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |